Research Study of Visilizumab for Treatment of Glucocorticoid- Refractory Graft Versus Host Disease

PHASE2UnknownINTERVENTIONAL
Enrollment

80

Participants

Timeline

Start Date

March 31, 2002

Conditions
Graft-vs-Host Disease
Interventions
DRUG

Visilizumab

Trial Locations (17)

10021

The New York Hospital Cornell Medical Center, New York

10595

Westchester Medical Center, Valhalla

27705

Duke University, Durham

33612

H. Lee Moffitt Cancer Center & Research Institute, Tampa

43210

Ohio State University, Columbus

44195

Cleveland Clinic Foundation, Cleveland

46202

University Hospital, Indianapolis

63110

Washington University School of Medicine, St Louis

75246

Baylor University Medical Center, Dallas

77030

Baylor College of Medicine, Houston

MD Anderson Cancer Center, Houston

91910

City of Hope National Medical Center, Duarte

98109

Fred Hutchinson Cancer Research Center, Seattle

94305-5623

Stanford University Medical Center, Stanford

02115

Dana Farber Cancer Institute, Boston

01605

University of Massachusetts Medical School, Worcester

37232-6310

Vanderbilt University Medical Center, Nashville

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Facet Biotech

INDUSTRY

lead

Fred Hutchinson Cancer Center

OTHER